Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/27/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. AWK
8. DRI
9. ULS
10. PRME

Go back to Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology

Eli Lilly (LLY) PT Raised to $115 at Credit Suisse

February 7, 2019 7:59 AM EST

Credit Suisse analyst Vamil Divan raised the price target on Eli Lilly (NYSE: LLY) to $115.00 (from $112.00) while maintaining a Neutral rating following the company's 4Q earnings report. Overall, 4Q18 was mixed, as revenues beat expectations but EPS missed forecasts by a... More

Eli Lilly (LLY) PT Raised to $143 at Cantor Fitzgerald

February 6, 2019 1:28 PM EST

Cantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $143.00 (from $128.00) while maintaining a Overweight rating.

Chen commented, "Post a modest 4Q18 EPS miss, we maintain our OW rating and increase our 12 month PT to $143... More

Eli Lilly & Co. (LLY) Misses Q4 EPS by 1c, Revenue Beats, FY19 EPS Guidance Misses

February 6, 2019 6:27 AM EST

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $1.33, $0.01 worse than the analyst estimate of $1.34. Revenue for the quarter came in at $6.44 billion versus the consensus estimate of $6.28 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2019 EPS of $5.55-$5.65, versus the... More